Novo Resources is advancing exploration at the Tibooburra Gold Project in NSW through a joint venture with Manhattan Gold Corporation. A ~2,700 meter reverse circulation (RC) drilling program is planned to begin in late Q3 2026, focusing on the Clone and Pioneer South prospects, both known for high-grade gold mineralization. The drilling aims to extend known gold zones and test new targets identified through ongoing regional sampling and mapping. This program follows promising results from previous campaigns and is part of Novo's strategy to develop a significant gold resource in the historically under-explored Albert Goldfields area.
Biotech stocks and leveraged ETFs were the biggest losers in the market, with Cue Biopharma dropping 23.7% despite positive Phase 2 clinical results. Leveraged ETFs tied to AMD, Strategy, and Novo Nordisk also saw sharp declines due to their daily-re...
Novo Nordisk's shares fell over 7% after the company announced long-term targets that failed to reassure investors about competition in the weight-loss drug market. The Danish drugmaker plans to launch multiple blockbuster drugs by 2030 and aims for ...
Novo Nordisk's stock fell 7% following its capital markets day where it outlined a growth plan that aligns with industry peers rather than exceeding them, signaling slower future growth. The company highlighted the upcoming loss of U.S. patent exclus...
Novo, a Danish pharmaceutical company, saw its shares fall up to 7% after announcing plans to launch over five new drugs with blockbuster potential by 2030 and targeting pipeline sales exceeding $23 billion by 2035. The company aims to grow revenue f...
Anthropic has revealed it operates a wet biology lab where its AI models conduct physical experiments, aiming to bridge AI theories with real-world biology. This lab functions like a typical biotech facility, supporting both in-house research and col...
